With its growing cardiometabolic portfolio and strong diagnostic expertise, Roche is advancing a portfolio of solutions providing optionality to adequately address the diverse needs of people living with obesity and its comorbidities.<\/p>\n
Obesity is recognised as the greatest single risk factor for chronic disease globally. By 2035, over four billion people (more than half of the global population) are projected to be living with overweight and obesity, a trend affecting nearly every country. This rise is driven by a complex mix of genetics and biology as well as behavioural, environmental and socioeconomic factors, placing an increased strain on healthcare systems due to the associated burden of comorbidities and reduced quality of life.<\/p>\n
In 2025, Roche and Zealand entered into an exclusive collaboration & licensing agreement to co-develop and co-commercialise petrelintide for people living with overweight and obesity.<\/p>\n
About ZUPREME-1 [NCT06662539]<\/p>\n
ZUPREME-1 is a 42-week randomised, double-blind, placebo-controlled, dose-finding Phase II clinical trial with 493 participants with a mean baseline body weight of 107 kg, a mean body mass index (BMI) of 37 kg\/m\u00b2, and a mean age of 48 years. The trial population was 53% female, representing a well-balanced cohort designed to maximise learning across genders. The trial compares five doses of once-weekly petrelintide with placebo, when added to a reduced-calorie diet and increased physical activity in people with obesity or overweight with weight-related comorbidities.<\/p>\n
The trial includes a screening period, a dose escalation period up to 16 weeks with dose escalation every fourth week, followed by a maintenance period until week 42, and a follow-up period after treatment is completed until week 51. ZUPREME-1 has enrolled participants across 33 sites in the United States, Poland, and Romania. The primary endpoint in the trial is the percentage change in body weight from baseline to week 28. Secondary endpoints include, but are not limited to, percentage change in body weight from baseline to week 42, change in waist circumference, change in haemoglobin A1c (HbA1c), change in high-sensitivity C-reactive protein (hsCRP), change in fasting lipids, and change in fasting glucose. Change in body composition at week 42 measured by Magnetic Resonance Imaging (MRI) is included as an exploratory endpoint in the trial.<\/p>\n
About Petrelintide<\/p>\n
Petrelintide is an investigational long-acting amylin analog suitable for once-weekly subcutaneous administration that has been designed with chemical and physical stability with no fibrillation around neutral pH, allowing for co-formulation and co-administration with other peptides.1 Amylin is produced in the pancreatic beta cells and co-secreted with insulin in response to ingested nutrients. Amylin receptor activation has been shown to reduce body weight by restoring sensitivity to the satiety hormone leptin2,3 inducing a sense of feeling full faster.<\/p>\n
About Roche<\/p>\n
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world\u2019s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.<\/p>\n
For over 125 years, sustainability has been an integral part of Roche\u2019s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.<\/p>\n
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.<\/p>\n
For more information, please visit www.roche.com<\/a>.<\/p>\n All trademarks used or mentioned in this release are protected by law.<\/p>\n References<\/p>\n [1] Eriksson et al. Presentation at ObesityWeek, November 1-4, 2022, San Diego, CA. Link: https:\/\/www.zealandpharma.com\/media\/0gnfxg4b\/zp8396-sema-coformulation-obesityweek-2022.pdf.<\/p>\n [2] Mathiesen et al. Eur J Endocrinol 2022;186(6):R93-R111<\/p>\n [3] Roth et al. Proc Natl Acad Sci U S A 2008;105(20):7257-7262<\/p>\n Roche Global Media Relations<\/p>\n
![\"\"](\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/03\/1772882349_128_F-Hoffmann-La-Roche-Ltd.png\"\/)
<\/p>\n","protected":false},"excerpt":{"rendered":"Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7% with placebo (p-valueAt the…\n","protected":false},"author":2,"featured_media":27194,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[16580,5203,16581,2438,16576,11434,4511,16578,14539,1813,16582,3008,16579,4001,16577,3552,134,3737],"class_list":["post-27193","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-amylin","tag-an","tag-analog","tag-and","tag-announces","tag-developed","tag-for","tag-ii","tag-living","tag-obesity","tag-overweight","tag-people","tag-petrelintide","tag-phase","tag-positive","tag-results","tag-roche","tag-with"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116187625088108277","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/27193","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=27193"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/27193\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/27194"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=27193"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=27193"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=27193"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}